NEW YORK (GenomeWeb) – Natera and Swiss biotech Amal Therapeutics plan to partner on a clinical trial to test Natera's bespoke circulating tumor DNA assay, Signatera, to assess treatment response in late-stage colorectal cancer patients.
The prospective clinical trial will assess Amal's cancer vaccine, ATP128, in combination with a PD-1 inhibitor in patients with stage IV colorectal cancer. Study investigators will use Signatera to measure patients' treatment response.
The trial "demonstrates the continued adoption of Signatera for use as a potential surrogate endpoint in clinical trials to evaluate treatment response and predict outcomes across a wide range of solid tumors," Alexey Aleshin, Natera's oncology medical director, said in a statement.
Natera CEO Steve Chapman added that the company now has more than 30 clinical trials with pharmaceutical companies underway that use its Signatera assay.